2 unknown, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow CAN1012: new trials by email Literature Review of CAN1012 trials Research Report on CAN1012
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CAN1012 in Pre-Malignant DCIS and LCIS CAN1012 - Ductal Carcinoma in Situ, Lobular Carcinoma in Situ | Phase 1 | Recruiting | Providence Health & Services | 24 | 2026-09-16 | 2026-09-24 |
| CAN1012 in Pre-malignant Oral Dysplasia CAN1012 - Oral Epithelial Dysplasia (OED) | Phase 1 | Not yet recruiting | Providence Health & Services | 36 | 2026-07-01 | 2026-06-02 |
| CAN1012 Combined With PD-1 in Patients With Solid Tumors CAN1012 - Advanced Solid Tumor | Phase 1 / Phase 2 | Unknown | Canwell Biotech Limited | 71 | 2024-06-27 | 2024-10-31 |
| Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors CAN1012 - Solid Tumor | Phase 1 | Active not recruiting | Canwell Biotech Limited | 27 | 2022-09-09 | 2025-02-13 |
| Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors CAN1012 - Solid Tumor, Cancer Metastatic | Phase 1 | Unknown | CanWell Pharma Inc. | 36 | 2022-01-20 | 2023-12-22 |
Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Neoplasm Metastasis (1)
Canwell Biotech Limited (2) · Providence Health & Services (2) · CanWell Pharma Inc. (1)
China (2) · United States (2)